Centre for Cancer Biomarkers CCBIO

CCBIO Special Career Seminar: From startup to pharmaceutical industry

As many of our students are curious of a career in the pharmaceutical industry, we have invited three representatives to tell us a little about that in a CCBIO Special Career Seminar.

Main content

What: CCBIO Special Career Seminar: From startup to pharmaceutical industry

When: April 5, 2024 at 11.30-12.30

Where: Campus Haukeland University Hospital, Auditorium B302, Sentralblokka 3rd floor

Who: aiming at early career researchers, PhD students, master students and medical students

Host: Bjørn Tore Gjertsen, Professor, CCBIO


  • Introduction: "Career Opportunities in biotech and startups", by Gro Gausdal, PhD, CEO, Bjørgvin Therapeutics Group AS. Gro has more than 10 years experience as a scientific researcher and director at a small biotech and is now taking the step forward as CEO in a new startup. How prepared will you be for industry career with a PhD in Medical Cell Biology? And why take the chance to go for a start up?
  • "Career Opportunities in the Pharmaceutical Industry", by Camille Claudius and Ann Theres Poblenz.
    Camille Claudius, MD, HD, Head of Medical Affairs, Astellas Nordics: Camille is a medical doctor who has done research in gynaecology and neurobiology amongst others. In 2002 she joined the pharmaceutical industry, having worked in many roles in both global, national and regional positions in clinical development, medical affairs and clinical trial operations. Before joining Astellas as the Head of Medical Affairs, she was the Country Medical Director at Amgen. Prior to that, she spent ~15 years in the headquarters of Novo Nordisk Global as an International Medical Director of different areas in Global development.  She is a board member of several board in Life Science.
    Ann Theres Poblenz, PhD, Medical Affairs Therapy Area Lead, Oncology, Astellas Nordics: Ann Theres completed her PhD thesis on apoptosis in CNS before transitioning to research in breast, and prostate cancer (with focus on bone metastases), and multiple melanoma at MD Anderson Cancer Center.  In 2005, she entered the pharmaceutical industry. Prior to her current role at Astellas, she served as the Country Medical Lead for Oncology at MSD in Denmark. Before that, she worked as a Medical Science Liaison in the United States and later held positions as a Medical Affairs Strategy Lead and Country Medical Affairs Director at Merck/MSD in the United States, focusing on pembrolizumab in hematology, women’s cancer and melanoma, as well as CINV.